A long-acting injectable antipsychotic agent used for chronic schizophrenia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ceritinib | Fluspirilene may increase the bradycardic activities of Ceritinib. |
| Ivabradine | Fluspirilene may increase the bradycardic activities of Ivabradine. |
| Ruxolitinib | Ruxolitinib may increase the bradycardic activities of Fluspirilene. |
| Buprenorphine | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. |
| Hydrocodone | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Fluspirilene can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. |
| Orphenadrine | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. |
| Rotigotine | Fluspirilene may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Fluspirilene. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Fluspirilene is combined with Sodium oxybate. |
| Suvorexant | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. |
| Thalidomide | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Fluspirilene may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Methylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene. |
| Metyrosine | Fluspirilene may increase the sedative activities of Metyrosine. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluspirilene. |
| Sulpiride | Fluspirilene may increase the antipsychotic activities of Sulpiride. |
| Cimetidine | The serum concentration of Fluspirilene can be increased when it is combined with Cimetidine. |
| Clopidogrel | The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Fluspirilene. |
| Efavirenz | The serum concentration of Fluspirilene can be decreased when it is combined with Efavirenz. |
| Melatonin | The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Melatonin. |
| Nafcillin | The therapeutic efficacy of Fluspirilene can be decreased when used in combination with Nafcillin. |
| Nitroprusside | Fluspirilene may increase the hypotensive activities of Nitroprusside. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene. |
| Mequitazine | Fluspirilene may increase the arrhythmogenic activities of Mequitazine. |
| Dantrolene | The risk or severity of hyperkalemia can be increased when Dantrolene is combined with Fluspirilene. |
| Lithium citrate | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lithium citrate. |
| Lithium carbonate | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lithium carbonate. |
| Lithium hydroxide | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Lithium hydroxide. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Fluspirilene. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenindione. |
| Coumarin | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Coumarin. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Tioclomarol. |
| Warfarin | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Fluspirilene is combined with 4-hydroxycoumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Fluspirilene is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Diphenadione. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Fluspirilene is combined with (S)-Warfarin. |
| Mirtazapine | Fluspirilene may increase the serotonergic activities of Mirtazapine. |
| Ethanol | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene. |
| Zimelidine | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Sibutramine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Fluspirilene. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Fluspirilene is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Fluspirilene is combined with Alaproclate. |
| Tocainide | Tocainide may increase the arrhythmogenic activities of Fluspirilene. |
| Aprindine | Aprindine may increase the arrhythmogenic activities of Fluspirilene. |
| Carteolol | Fluspirilene may increase the arrhythmogenic activities of Carteolol. |
| Metipranolol | Fluspirilene may increase the arrhythmogenic activities of Metipranolol. |
| Xylometazoline | Fluspirilene may increase the arrhythmogenic activities of Xylometazoline. |
| Sparteine | Fluspirilene may increase the arrhythmogenic activities of Sparteine. |
| Fasudil | Fluspirilene may increase the arrhythmogenic activities of Fasudil. |
| Spiradoline | Fluspirilene may increase the arrhythmogenic activities of Spiradoline. |
| Tiracizine | Fluspirilene may increase the arrhythmogenic activities of Tiracizine. |
| Ethacizine | Fluspirilene may increase the arrhythmogenic activities of Ethacizine. |
| Hydroquinine | Fluspirilene may increase the arrhythmogenic activities of Hydroquinine. |
| Bioallethrin | Fluspirilene may increase the arrhythmogenic activities of Bioallethrin. |
| Fosfructose | Fluspirilene may increase the arrhythmogenic activities of Fosfructose. |
| Hydroquinidine | Fluspirilene may increase the arrhythmogenic activities of Hydroquinidine. |
| SOR-C13 | Fluspirilene may increase the arrhythmogenic activities of SOR-C13. |
| Digoxin | Digoxin may increase the arrhythmogenic activities of Fluspirilene. |
| Acetyldigitoxin | Acetyldigitoxin may increase the arrhythmogenic activities of Fluspirilene. |
| Deslanoside | Deslanoside may increase the arrhythmogenic activities of Fluspirilene. |
| Cymarin | Fluspirilene may increase the arrhythmogenic activities of Cymarin. |
| Metildigoxin | Fluspirilene may increase the arrhythmogenic activities of Metildigoxin. |
| Acetyldigoxin | Fluspirilene may increase the arrhythmogenic activities of Acetyldigoxin. |
| Disopyramide | Disopyramide may increase the arrhythmogenic activities of Fluspirilene. |
| Ibutilide | Ibutilide may increase the arrhythmogenic activities of Fluspirilene. |
| Procainamide | Procainamide may increase the arrhythmogenic activities of Fluspirilene. |
| Bepridil | Bepridil may increase the arrhythmogenic activities of Fluspirilene. |
| Terodiline | Fluspirilene may increase the arrhythmogenic activities of Terodiline. |
| Diltiazem | Diltiazem may increase the arrhythmogenic activities of Fluspirilene. |